 The objective of this study is to prospectively monitor the incidence of adverse drug reactions, specifically NSF during routine use of gadoversetamide in a large number of patients with moderate renal insufficiency eGFR 30-59 and severe renal insufficiency or end-stage renal disease requiring dialysis eGFR 30. 